What's Happening?
The Department of Justice (DOJ) and the Department of Health and Human Services (HHS) have introduced new pilot programs designed to streamline the process for healthcare organizations to voluntarily disclose potential fraud. On October 15, 2026, the DOJ's
National Fraud Enforcement Division and the HHS Office of Inspector General (HHS-OIG) announced that a single disclosure of potentially criminal healthcare conduct to the Fraud Division would now qualify for benefits under both the DOJ's Corporate Enforcement Policy (CEP) and HHS-OIG's Self-Disclosure Protocol (OIG SDP). Following this, on October 22, the DOJ's Civil Division, HHS-OIG, and the Centers for Medicare and Medicaid Services (CMS) launched a six-month Healthcare False Claims Act Self-Disclosure Pilot Program. This civil pilot offers a coordinated civil release, no admissions, no Corporate Integrity Agreement (CIA), and a fixed repayment multiplier for potential False Claims Act (FCA) violations previously unknown to the federal government. These initiatives aim to create a more predictable environment for self-disclosure, building on the department-wide CEP issued earlier in March 2026.
Why It's Important?
These new self-disclosure pilot programs are significant for healthcare providers, suppliers, manufacturers, payors, and related entities involved with HHS federal healthcare programs. The coordinated approach between the DOJ and HHS-OIG simplifies the disclosure process, potentially reducing the burden on organizations that identify and report fraud. The civil pilot's offer of a fixed repayment multiplier and the absence of a Corporate Integrity Agreement could incentivize more companies to come forward, as it provides a clearer path to resolution with potentially lower penalties than traditional enforcement actions. This could lead to a more efficient recovery of funds lost to fraud and a stronger emphasis on compliance within the healthcare industry. Companies that act promptly and thoroughly in disclosing potential violations stand to gain from these programs, while those that delay or whose violations are discovered by the government prior to disclosure may miss out on these benefits, facing more severe consequences.
What's Next?
The civil pilot program for Healthcare False Claims Act self-disclosure is set to close on April 22, 2027. Healthcare organizations with potential compliance issues or those conducting internal reviews are encouraged to act swiftly to assess their exposure and consider participating in the program before the deadline. Companies will need to determine whether a problem is civil, criminal, or both, and decide which disclosure pathway to utilize first. The programs emphasize the importance of complete submissions, including detailed narratives, supporting documents, and financial data. Organizations should also be aware that prior government knowledge of a violation may preclude them from receiving pilot resolution benefits. The success and impact of these pilot programs will likely be evaluated after their conclusion, potentially leading to permanent changes in how healthcare fraud is addressed and resolved by federal agencies.
Beyond the Headlines
The introduction of these parallel self-disclosure pathways highlights a broader shift in the federal government's strategy for combating healthcare fraud. By offering more predictable and potentially less punitive resolutions for voluntary disclosures, the DOJ and HHS are attempting to foster a culture of proactive compliance within the healthcare sector. This approach could lead to a more collaborative relationship between government regulators and healthcare entities, moving away from solely punitive measures. However, it also places a significant onus on organizations to conduct thorough internal investigations and make timely disclosures. The programs also raise questions about the civil-criminal line, particularly for Anti-Kickback Statute violations, and the implications for companies that may have ongoing qui tam actions. The emphasis on early and complete disclosure underscores the increasing complexity of healthcare compliance and the need for organizations to have robust internal controls and legal counsel.
